Pinnbrook Capital Management LP Takes $4.19 Million Position in Novo Nordisk A/S (NYSE:NVO)

Pinnbrook Capital Management LP acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 40,468 shares of the company's stock, valued at approximately $4,186,000.

Several other large investors have also made changes to their positions in the business. Pacific Center for Financial Services increased its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company's stock worth $26,000 after acquiring an additional 141 shares during the last quarter. Bell Investment Advisors Inc increased its stake in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock worth $26,000 after acquiring an additional 127 shares during the last quarter. CNB Bank bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Finally, Citizens National Bank Trust Department increased its stake in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company's stock worth $27,000 after acquiring an additional 150 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 1.3 %

Shares of NYSE:NVO traded up $1.63 during trading hours on Monday, hitting $127.49. 3,015,453 shares of the company's stock traded hands, compared to its average volume of 5,108,126. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The business has a fifty day moving average price of $125.00 and a 200-day moving average price of $108.92. The firm has a market capitalization of $572.12 billion, a P/E ratio of 47.13, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a $0.664 dividend. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S's payout ratio is presently 49.17%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price objective on the stock. UBS Group started coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a "neutral" rating on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.